Your browser doesn't support javascript.
loading
Plasma glucagon-like peptide-1 responses to ingestion of protein with increasing doses of milk minerals rich in calcium.
Watkins, Jonathan D; Smith, Harry A; Hengist, Aaron; Brunsgaard, Lise Høj; Mikkelsen, Ulla Ramer; Koumanov, Francoise; Betts, James A; Gonzalez, Javier T.
Afiliação
  • Watkins JD; Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, Bath, UK.
  • Smith HA; Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, Bath, UK.
  • Hengist A; Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, Bath, UK.
  • Brunsgaard LH; Arla Foods Ingredients Group P/S, Viby J, Denmark.
  • Mikkelsen UR; Arla Foods Ingredients Group P/S, Viby J, Denmark.
  • Koumanov F; Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, Bath, UK.
  • Betts JA; Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, Bath, UK.
  • Gonzalez JT; Centre for Nutrition, Exercise and Metabolism, Department for Health, University of Bath, Bath, UK.
Br J Nutr ; : 1-9, 2021 Aug 09.
Article em En | MEDLINE | ID: mdl-34369333
ABSTRACT
A high dose of whey protein hydrolysate fed with milk minerals rich in calcium (Capolac®) results in enhanced glucagon-like peptide-1 (GLP-1) concentrations in lean individuals; however, the effect of different calcium doses ingested alongside protein is unknown. The present study assessed the dose response of calcium fed alongside 25 g whey protein hydrolysate on GLP-1 concentrations in individuals with overweight/obesity. Eighteen adults (mean ± sd 8M/10F, 34 ± 18 years, 28·2 ± 2·9 kgm-2) completed four trials in a randomised, double-blind, crossover design. Participants consumed test solutions consisting of 25 g whey protein hydrolysate (CON), supplemented with 3179 mg (LOW), 6363 mg (MED) or 9547 mg (HIGH) Capolac® on different occasions, separated by at least 48 h. The calcium content of test solutions equated to 65, 892, 1719 and 2547 mg, respectively. Arterialised-venous blood was sampled over 180 min to determine plasma concentrations of GLP-1TOTAL, GLP-17-36amide, insulin, glucose, NEFA, and serum concentrations of calcium and albumin. Ad libitum energy intake was measured at 180 min. Time-averaged incremental AUC (iAUC) for GLP-1TOTAL (pmol·l-1·min-1) did not differ between CON (23 ± 4), LOW (25 ± 6), MED (24 ± 5) and HIGH (24 ± 6). Energy intake (kcal) did not differ between CON (940 ± 387), LOW (884 ± 345), MED (920 ± 334) and HIGH (973 ± 390). Co-ingestion of whey protein hydrolysate with Capolac® does not potentiate GLP-1 release in comparison with whey protein hydrolysate alone. The study was registered at clinical trials (NCT03819972).
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article